The 24 patient, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura over six weeks of treatment.
John Higgins, president and CEO of Ligand, said: “We plan to initiate additional clinical studies with LGD-4665 this year. Our thrombopoietin drug program is focused on developing LGD-4665 for multiple indications as well as advancing clinically distinctive next generation molecules.”